NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
PHILADELPHIA, Dec. 18, 2023 -- (Healthcare Sales & Marketing Network) -- On December 7, 2023, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation ("ODD") to NXL-004, an investigational AAV gene therapy product being devel... Regenerative Medicine, Neurosurgery, Oncology, FDA NeuExcell Therapeutics, malignant glioma, gene therapy, glioblastoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brain | Brain Tumor | Cancer & Oncology | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Glioma | Marketing | Neurology | Neurosurgery | Pharmaceuticals